混合细胞型肝癌的诊疗研究进展

Progress in the diagnosis and treatment of combined hepatocellular-cholangiocarcinoma

混合细胞型肝癌是一种罕见且具有较强侵袭性的原发性肝脏恶性肿瘤,具有显著的组织学和生物学异质性。与肝细胞癌或肝内胆管细胞癌相比,混合细胞型肝癌术前诊断较为困难且预后更差。研究混合细胞型肝癌的遗传和分子表型将有助于更好地了解其发病机制和发现新的治疗策略。本文回顾近年来关混合细胞型肝癌诊疗的研究进展,探讨其在病理学、遗传学、临床表现、诊断、治疗等方面区别于肝细胞癌和肝内胆管细胞癌的特点,并展望其未来的研究方向。

Combined hepatocellular-cholangiocarcinoma is a rare and aggressive primary liver malignant tumor with significant histological and biological heterogeneity.It has worse survival than either hepatocellular carcinoma or cholangiocarcinoma and because it’s difficultly to be diagnosed.Understanding the genetic and molecular phenotypes of combined hepatocellular-cholangiocarcinoma will help us to identify the pathogenesis and develop new treatment strategies.This article reviewed the recent research progress on the diagnosis and treatment of combined hepatocellular-cholangiocarcinoma,and explored its characteristics that are different from hepatocellular carcinoma and intrahepatic cholangiocarcinoma in pathology,genetics,clinical manifestations,diagnosis,and treatment,and looks forward to its future research.